NCT00004856终止2 期
A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Objective response rate (complete or partial response) as assessed by RECIST criteria
研究概览
简要总结
Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
详细描述
OBJECTIVES:
I. Determine the response rate in patients with previously treated, locally advanced or metastatic transitional cell carcinoma of the urothelium treated with trastuzumab (Herceptin).
II. Determine the safety of this drug in this patient population. III. Determine overall and progression-free survival of this patient population treated with this drug.
OUTLINE:
Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed transitional cell carcinoma (TCC) of the urothelium, including the bladder, urethra, ureter, or renal pelvis
- •No pure adenocarcinomas, pure squamous cell carcinomas, small cell carcinoma, or only small foci of TCC (less than 10% of tumor specimen)
- •Locally advanced (T4b) TCC of the bladder
- •Metastatic (N2 or N3 or M1)TCC of the urothelium
- •HER2 expression (3+) as determined by immunohistochemistry or gene amplification by fluorescent in situ hybridization
- •Must not be a candidate for potentially curative surgery or radiotherapy
- •Measurable disease
- •At least 1 unidimensionally measurable lesion of at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- •The following lesions are considered nonmeasurable:
- •Bone lesions
- •Leptomeningeal disease
- •Pleural/pericardial effusion
- •Lymphangitis cutis/pulmonis
- •Abdominal masses not confirmed and followed by imaging techniques
- •Cystic lesions
- •Primary bladder masses
- •Relapsed from or failed to achieve a complete or partial response after 1 prior systemic chemotherapy regimen for TCC, including cisplatin, carboplatin, paclitaxel, docetaxel, or gemcitabine
- •Prior adjuvant or neoadjuvant chemotherapy is considered 1 prior chemotherapy regimen
- •Prior single-agent chemotherapy as a radiosensitizer is not considered a prior systemic chemotherapy regimen
- •No known brain metastases
- •Performance status - CTC 0-2
- •More than 12 weeks
- •Absolute neutrophil count at least 1,000/mm^3
- •Platelet count at least 75,000/mm^3
- •Bilirubin no greater than 2 times upper limit of normal (ULN)
- •AST no greater than 2 times ULN
- •Creatinine clearance at least 30 mL/min
- •Ejection fraction at least 50% (or lower limit of normal) by echocardiogram or MUGA
- •No history of ongoing congestive heart failure
- •No active cardiac ischemia
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- •HIV negative
- •No known autoimmune disease
- •No prior trastuzumab (Herceptin)
- •At least 14 days since prior radiotherapy
- •At least 30 days since prior chemotherapy
- •Prior doxorubicin allowed provided cumulative dose is no greater than 300 mg/m^2
- •Prior epirubicin allowed provided cumulative dose is no greater than 600 mg/m^2
- •No concurrent chemotherapy
- •No concurrent hormonal therapy except:
- •Steroids given for adrenal failure
- •Hormones administered for nondisease-related conditions (e.g., insulin for diabetes)
- •Intermittent dexamethasone as an antiemetic or for sensitivity reactions to study drug
- •No concurrent palliative radiotherapy
- •Prior radiotherapy allowed provided treated area is not only site of measurable disease
- •At least 14 days since prior surgery
排除标准
- 未提供
结局指标
主要结局
Objective response rate (complete or partial response) as assessed by RECIST criteria
时间窗: 1 year
次要结局
- Overall survival (OS)(From date of initiation of treatment to date of death due to any cause, assessed up to 1 year)
- Disease-free survival (DFS)(From date of initiation of treatment to date of progression or death due to any cause, whichever occurs first, assessed up to 1 year)
- Toxicities as graded according to the NCI Common Toxicity Criteria(12 weeks)
- Proportion of patients who are HER2 positive (3+ by IHC or FISH positive)(Baseline)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00004883National Cancer Institute (NCI)84
终止
2 期
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryAdenocarcinoma of the Extrahepatic Bile DuctAdenocarcinoma of the GallbladderMalignant NeoplasmRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00478140National Cancer Institute (NCI)4
已完成
2 期
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterSquamous Cell Carcinoma of the BladderStage IV Bladder CancerTransitional Cell Carcinoma of the BladderNCT00005831National Cancer Institute (NCI)40
已完成
2 期
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial CancerUrologic NeoplasmsNCT00151034University of Michigan Rogel Cancer Center33
终止
2 期
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerHigh-grade Salivary Gland Mucoepidermoid CarcinomaRecurrent Salivary Gland CancerSalivary Gland Acinic Cell TumorSalivary Gland AdenocarcinomaSalivary Gland Poorly Differentiated CarcinomaStage IVA Salivary Gland CancerStage IVB Salivary Gland CancerStage IVC Salivary Gland CancerNCT00126607National Cancer Institute (NCI)35